Source: Research Seminar 2005 - Pulmonary Circulation: Molecular Determinants of Pulmonary Vascular Remodelling
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Humbert (Clamart, France). Cytokines and chemokines in pulmonary vascular remodelling. Research Seminar 2005 - Pulmonary Circulation: Molecular Determinants of Pulmonary Vascular Remodelling

Member's Comments

No comment yet.

Related content which might interest you: The role of chemokines and cytokines in lung fibrosis Source: Eur Respir Rev 2008; 17: 151-156 Year: 2008 The role of pathological angiogenesis in the pathogenesis of the chronic inflammatory lung diseases Source: Annual Congress 2005 - Update on the role of angiogenesis in the pathogenesis and treatment of lung diseases Year: 2005 Role of cytokines and chemokines in bronchial hyperresponsiveness and airway inflammation and remodelling Source: Annual Congress 2007 - PG1 - Asthma: from bench to bedside Year: 2007 Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension Source: Eur Respir J 2009; 34: 662 Year: 2009 Proinflammatory cytokine levels are linked to death in pulmonary arterial hypertension Source: Eur Respir J 2014; 43: 915-917 Year: 2014 Pro-inflammatory cytokines in pathogenesis professional occupetional pulmonary disease Source: Eur Respir J 2004; 24: Suppl. 48, 148s Year: 2004 Inflammation in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: 358-363 Year: 2003 Role of IL-11 in vascular function of pulmonary fibrosis patients Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019 M2 macrophages derived from patients with idiopathic pulmonary arterial hypertension are susceptible for apelin-mediated suppression of pro-inflammatory cytokines Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Pulmonary interstitium remodeling by collagen V is associated with profibrotic cytocines in experimental systemic sclerosis Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases Year: 2007 Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension Source: Eur Respir J 2010; 36: 1302-1314 Year: 2010 The interleukin 13 receptor system is altered in pulmonary arterial hypertension Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling Year: 2006 FIZZ1: a new pathway in silica-induced inflammatory mediators and pulmonary fibrosis Source: International Congress 2018 – Occupational and environmental lung diseases: mechanisms, biomarkers and causation Year: 2018 Role of mast cells and chymase in pulmonary vascular remodeling Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension Year: 2011 Cytokines status, endothelial function in patients with pulmonary diseases Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases Year: 2008 Cytokines in pathogenesis of pulmonary tuberculosis Source: Annual Congress 2011 - Tuberculosis: from bench to bedside Year: 2011 Role of TGF-beta and IFN-gamma in interstitial pulmonary fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 719s Year: 2004 Increased fibrinolytic mediators in IPF as potential contributors to pulmonary fibrosis and vascular remodeling Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Cytokines and the lung Source: Eur Respir J 2001; 18: 3S-17S Year: 2001